Thiogenesis Therapeutics, Corp. (TSXV:TTI)

Canada flag Canada · Delayed Price · Currency is CAD
0.500
0.00 (0.00%)
Mar 9, 2026, 2:21 PM EST
-16.67%
Market Cap 25.92M
Revenue (ttm) n/a
Net Income (ttm) -6.82M
Shares Out 51.84M
EPS (ttm) -0.14
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 45,000
Average Volume 21,485
Open 0.500
Previous Close 0.500
Day's Range 0.500 - 0.500
52-Week Range 0.500 - 0.880
Beta 0.46
RSI 28.69
Earnings Date Apr 24, 2026

About Thiogenesis Therapeutics

Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs. Its lead product candidate is TTI-0102, a prodrug that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke-like episodes, leigh syndrome, pediatric metabolic dysfunction-associated steatohepatitis, and rett syndrome. The company is headquartered in Toronto, Canada. [Read more]

Industry Biotechnology
Sector Healthcare
CEO Patrice Rioux
Country Canada
Stock Exchange TSX Venture Exchange
Ticker Symbol TTI
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.